

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:29:06 ON 11 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:29:15 ON 11 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 AUG 2008 HIGHEST RN 1040032-70-9
DICTIONARY FILE UPDATES: 10 AUG 2008 HIGHEST RN 1040032-70-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10574676a.str



```

chain nodes :
15 16 17 19 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
1-19 8-10 9-21 11-15 15-16 15-17 19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :
1-19 4-7 5-9 7-8 8-9 9-21 10-14 11-12 11-15 19-22
exact bonds :
8-10 10-11 12-13 13-14 15-16 15-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 10 :

```

G1:O,S,N,Cy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 19:CLASS
21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:29:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 171 TO ITERATE

100.0% PROCESSED 171 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2636 TO 4204


PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1


=> d scan

L2 5 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Phenol, 3-[3-amino-1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-,
 2,2,2-trifluoroacetate (1:2)
 MF C24 H27 N7 O4 . 2 C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full
FULL SEARCH INITIATED 09:29:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3536 TO ITERATE

100.0% PROCESSED 3536 ITERATIONS 178 ANSWERS
SEARCH TIME: 00.00.01

L3 178 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 09:29:49 ON 11 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Aug 2008 VOL 149 ISS 7
FILE LAST UPDATED: 10 Aug 2008 (20080810/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3 full
L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1324378 CAPLUS

DOCUMENT NUMBER: 146:220117

TITLE: Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

AUTHOR(S): Stavenger, Robert A.; Cui, Haifeng; Dowdell, Sarah E.; Franz, Robert G.; Gaitanopoulos, Dimitri E.; Goodman, Krista B.; Hilfiker, Mark A.; Ivy, Robert L.; Leber, Jack D.; Marino, Joseph P., Jr.; Oh, Hye-Ja; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Zhang, Daohua; Zhao, Yongdong; Jolivet, Larry J.; Head, Martha S.; Semus, Simon F.; Elkins, Patricia A.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Doe, Christopher P.; Bentley, Ross; Chen, Zunxuan X.; Hu, Erding; Lee, Dennis

CORPORATE SOURCE: Department of Medicinal Chemistry, GlaxoSmithKline, King of Prussia, PA, 19406, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(1), 2-5
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:220117

AB The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.


IT 607373-85-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity)

RN 607373-85-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1124305 CAPLUS
DOCUMENT NUMBER: 145:471527
TITLE: Imidazopyridinyl compounds as inhibitors of AKT activity and their preparation, pharmaceutical compositions and use in the treatment of cancer and arthritis
INVENTOR(S): Heerding, Dirk A.; Rouse, Meagan B.; Seefeld, Mark Andrew
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 198pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113837	A2	20061026	WO 2006-US14807	20060420
WO 2006113837	A3	20070830		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1874768	A2	20080109	EP 2006-758426	20060420
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRIORITY APPLN. INFO.:			US 2005-673120P	P 20050420
			WO 2006-US14807	W 20060420

OTHER SOURCE(S): MARPAT 145:471527
GI



AB Disclosed in the invention are 1H-imidazo[4,5-c]pyridin-2-yl compds. of formula I, the use of such compds. as inhibitors of protein kinase B


activity and in the treatment of cancer and arthritis. Compds. of formula I wherein Het is (un)substituted aminoxadiazolyl, (un)substituted pyridinyl, (un)substituted aminoisoxazolyl, (un)substituted pyrazinyl, and (un)substituted aminopyrimidinyl; R1 is H, (un)substituted alkyl, (un)substituted (hetero)cycloalkyl, (un)substituted C1-12 aryl, etc.; R4 and R7 are independently H, halo, (un)substituted alkyl, (un)substituted alkoxy, acetamide, CN, (un)substituted urea, (un)substituted aryl, oxo, OH, etc.; R15 is halo, (un)substituted alkyl, (un)substituted alkoxy, acetamide, CN, (un)substituted urea, (un)substituted aryl, oxo, OH, etc.; and their pharmaceutically acceptable salts, hydrates, solvates, and prodrugs are claimed. Example compound II was prepared by palladium-catalyzed coupling of 4-(6-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine with 2-hydroxy-2-methyl-3-butyne. All the invention compds. were evaluated for their protein kinase B inhibitory activity. From the assay, it was determined that some of the tested compds. exhibited IC50 valued of less than or equal to 0.5 μ M against AKT1, AKT2 and AKT3.

IT 913641-47-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of imidazopyridinyl compds. as protein kinase B activity inhibitors useful in treatment of cancer and arthritis)

RN 913641-47-1 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(3-methoxyphenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



IT 913640-06-9P 913640-07-0P 913640-08-1P
913640-15-0P 913640-28-5P 913640-29-6P
913640-30-9P 913640-31-0P 913640-32-1P
913640-34-3P 913640-36-5P 913640-41-2P
913640-43-4P 913640-45-6P 913640-48-9P
913640-49-0P 913640-50-3P 913640-51-4P
913640-52-5P 913640-53-6P 913640-54-7P
913640-55-8P 913640-56-9P 913640-57-0P
913640-58-1P 913640-59-2P 913640-60-5P
913640-61-6P 913640-62-7P 913640-63-8P
913640-64-9P 913640-68-3P 913640-69-4P
913640-71-8P 913640-72-9P 913640-73-0P
913640-74-1P 913640-75-2P 913640-76-3P
913640-77-4P 913640-78-5P 913640-79-6P
913640-80-9P 913640-81-0P 913640-82-1P
913640-83-2P 913640-84-3P 913640-86-5P
913640-87-6P 913640-88-7P 913640-89-8P
913640-90-1P 913640-91-2P 913640-92-3P
913641-01-7P 913641-02-8P 913641-03-9P


913641-04-0P 913641-05-1P 913641-06-2P
 913641-07-3P 913641-08-4P 913641-09-5P
 913641-10-8P 913641-12-0P 913641-13-1P
 913641-18-6P 913641-19-7P 913641-20-0P
 913641-21-1P 913641-22-2P 913641-23-3P
 913641-24-4P 913641-25-5P 913641-26-6P
 913641-27-7P 913641-28-8P 913641-29-9P
 913641-31-3P 913641-32-4P 913641-33-5P
 913641-34-6P 913641-35-7P 913641-36-8P
 913641-38-0P 913641-39-1P 913641-40-4P
 913641-41-5P 913641-42-6P 913641-43-7P
 913641-44-8P 913641-45-9P 913641-46-0P
 913641-48-2P 913641-49-3P 913641-50-6P
 913641-51-7P 913641-52-8P 913641-53-9P
 913641-54-0P 913641-55-1P 913641-56-2P
 913641-57-3P 913641-58-4P 913641-59-5P
 913641-60-8P 913641-61-9P 913641-62-0P
 913641-63-1P 913641-64-2P 913641-65-3P
 913641-66-4P 913641-67-5P 913641-68-6P
 913641-69-7P 913641-70-0P 913641-71-1P
 913641-72-2P 913641-73-3P 913641-74-4P
 913641-75-5P 913641-76-6P 913641-77-7P
 913641-79-9P 913641-80-2P 913641-81-3P
 913641-82-4P 913641-83-5P 913641-84-6P
 913641-85-7P 913641-86-8P 913641-87-9P
 913641-88-0P 913641-89-1P 913641-90-4P
 913641-91-5P 913641-92-6P 913641-93-7P
 913641-94-8P 913641-95-9P 913641-96-0P
 913641-97-1P 913641-98-2P 913641-99-3P
 913642-00-9P 913642-01-0P 913642-02-1P
 913642-03-2P 913642-04-3P 913642-05-4P
 913643-53-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of imidazopyridinyl compds. as protein kinase B
 activity inhibitors useful in treatment of cancer and arthritis)


RN 913640-06-9 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-(aminomethyl)phenyl]-2-(4-amino-1,2,5-oxadiazol-3-
 yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-07-0 CAPLUS

CN Benzonitrile, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-
 methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]- (CA INDEX NAME)




RN 913640-08-1 CAPLUS

CN Benzenemethanol, 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]- (CA INDEX NAME)




RN 913640-15-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-(aminomethyl)phenyl]-1-ethyl-4-(1H-pyrrol-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913640-28-5 CAPLUS


CN 3-Butyn-2-ol, 4-[6-(4-aminobutoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-29-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-30-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(5-aminopentyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-31-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(4-piperidinyloxy)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-32-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(3-pyrrolidinyloxy)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-34-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-36-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(2-morpholinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-41-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-(3-thienyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-43-4 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(1H-indol-3-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-45-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(methylamino)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-48-9 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(phenylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-49-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-50-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(3-piperidinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-51-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(3-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-52-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(1H-indol-3-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-53-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(2R)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-54-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(2S)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-55-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(1H-indol-3-

yl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-56-9 CAPLUS


CN 3-Butyn-2-ol, 4-[6-(4-amino-2-methylbutoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-57-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-2-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-58-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-2-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-59-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-60-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-61-6 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-methylbutoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-62-7 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]- (CA INDEX NAME)



RN 913640-63-8 CAPLUS


CN 2-Propyn-1-ol, 3-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]- (CA INDEX NAME)



RN 913640-64-9 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-azetidinylmethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-68-3 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(2-morpholinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-69-4 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[3-(2S)-2-pyrrolidinylpropoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-71-8 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-aminopropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-72-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-methylbutoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-73-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[[(2R)-2-amino-4-methylpentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-74-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[[(2S)-2-amino-4-methylpentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-75-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-aminopropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-76-3 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-cyclohexylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-77-4 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-4-phenylbutoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-78-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[6-(2-aminoethoxy)-1-ethyl-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 913640-79-6 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(1H-imidazol-5-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-80-9 CAPLUS

CN 2-Pyrrolidinone, 5-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-81-0 CAPLUS


CN 2-Pyrrolidinone, 5-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-82-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(1-pyrrolidinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-83-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-[(4-methoxyphenyl)methyl]amino]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-84-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-[[[4-(trifluoromethyl)phenyl]methyl]amino]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-86-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(4-morpholinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-87-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(phenylamino)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-88-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(1-methyl-1H-indol-3-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-89-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-[(phenylmethyl)thio]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-90-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-(3-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-91-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-4-phenylbutoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-92-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(2-amino-1-phenylethoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-01-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1R)-2-amino-1-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913641-02-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(methylamino)-1-phenylethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)



RN 913641-03-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(2-amino-1-cyclohexylethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-04-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(tetrahydro-2H-pyran-4-yl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)




RN 913641-05-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(3-pyridinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-06-2 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(2-amino-1-cyclopropylethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-07-3 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(1,3-benzodioxol-4-yl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-08-4 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(1R)-2-amino-1-(1,3-benzodioxol-4-yl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-09-5 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(1S)-2-amino-1-(1,3-benzodioxol-4-yl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-10-8 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-(dimethylamino)-1-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-12-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(S)-(2R)-2-morpholinylphenylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-13-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(R)-(2S)-2-morpholinylphenylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-18-6 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-(4-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-19-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1S)-2-amino-1-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913641-20-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(2-amino-1-methylethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-21-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[1-(aminomethyl)-2-phenylethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-22-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-amino-1-phenylpropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-23-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1S)-3-amino-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-24-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1R)-3-amino-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913641-25-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(3-amino-1-cyclohexylpropoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-26-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(4-pyridinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-27-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(2-pyridinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-28-8 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[1-(aminomethyl)-3-phenylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-29-9 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-amino-1-phenylbutoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-31-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(S)-phenyl(2S)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-32-4 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(R)-phenyl(2R)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-33-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(4-piperidinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-34-6 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(1-methyl-4-piperidinyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-35-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[3-amino-1-(4-piperidinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-36-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(1-methyl-4-piperidinyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-38-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(1R)-2-amino-1-cyclohexylethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-39-1 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(1S)-2-amino-1-cyclohexylethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-40-4 CAPLUS


CN 1-Pentyn-3-ol, 1-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-3-methyl- (CA INDEX NAME)




RN 913641-41-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1R,2S)-2-amino-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913641-42-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[3-(methylamino)-1-phenylpropoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-43-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[3-(dimethylamino)-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-44-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(4-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-45-9 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(3-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-46-0 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(2-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-48-2 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(1S,2S)-2-amino-3-methoxy-1-phenylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-49-3 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(2-fluoro-3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-50-6 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-51-7 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(2-fluoro-3-methoxyphenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-52-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(2-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-53-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(4-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-54-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-55-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-[2-(trifluoromethyl)phenyl]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-56-2 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(4-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913641-57-3 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
(CA INDEX NAME)

Absolute stereochemistry.




RN 913641-58-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-59-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-[3-(trifluoromethyl)phenyl]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-60-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-61-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-[4-(trifluoromethyl)phenyl]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-62-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-benzo[b]thien-2-ylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-63-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-cyclohexylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-64-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-amino-3-phenylpropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-65-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-amino-2-phenylpropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-66-4 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(3-chlorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-67-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(2-chlorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-68-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(4-chlorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-69-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(3-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-70-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(4-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-71-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(2-fluorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-72-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(3-fluorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-73-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(4-fluorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-74-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(4-fluoro-3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-75-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(4-fluoro-3-methoxyphenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-76-6 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-furanyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-77-7 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-furanyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-76-6

CMF C22 H25 N7 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 913641-79-9 CAPLUS

CN Phenol, 3-[2-amino-1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-78-8


CMF C23 H25 N7 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-80-2 CAPLUS

CN Phenol, 4-[(2R)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-81-3 CAPLUS


CN Phenol, 4-[(2R)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-80-2

CMF C24 H27 N7 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-82-4 CAPLUS

CN Phenol, 4-[(2S)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-83-5 CAPLUS


CN Phenol, 4-[(2S)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-82-4

CMF C24 H27 N7 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-84-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-85-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 913641-84-6
 CMF C25 H27 N7 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 913641-86-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-87-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 913641-86-8
 CMF C25 H29 N7 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 913641-88-0 CAPLUS
 CN Phenol, 3-[3-amino-1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-(CA INDEX NAME)




RN 913641-89-1 CAPLUS

CN Phenol, 3-[3-amino-1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-88-0


CMF C24 H27 N7 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-90-4 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-91-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 913641-90-4
 CMF C26 H29 N7 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 913641-92-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-(3-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-93-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-(4-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-94-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(4-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-95-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(2-furanyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-96-0 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-97-1 CAPLUS


CN 3-Butyn-2-ol, 4-[6-(3-amino-3-cyclohexylpropoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-98-2 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(3R)-3-amino-3-(tetrahydro-2H-pyran-4-yl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-99-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(3S)-3-amino-3-(tetrahydro-2H-pyran-4-yl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913642-00-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913642-01-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-(aminomethyl)-4-phenylbutoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913642-02-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-[(3-methoxyphenyl)methyl]propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)



RN 913642-03-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[3-amino-1-(3-thienylmethyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)




RN 913642-04-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-[(3,4-dimethoxyphenyl)methyl]propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)




RN 913642-05-4 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913643-53-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2,3-dihydro-1H-indol-2-yl)methoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



IT 913642-17-8P 913642-18-9P 913642-23-6P

913642-24-7P 913642-25-8P 913642-26-9P

913642-27-0P 913642-28-1P 913642-29-2P

913642-30-5P 913642-64-5P 913642-65-6P


913642-72-5P 913642-73-6P 913642-75-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazopyridinyl compds. as protein kinase B activity inhibitors useful in treatment of cancer and arthritis)


RN 913642-17-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-(aminomethyl)phenyl]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913642-18-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-(aminomethyl)phenyl]-1-ethyl-4-[1-[tris(1-methylethyl)silyl]-1H-pyrrol-3-yl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913642-23-6 CAPLUS

CN Carbamic acid, [4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 913642-24-7 CAPLUS


CN Carbamic acid, [4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 913642-25-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-6-(phenylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913642-26-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(4-methoxyphenyl)methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913642-27-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913642-28-1 CAPLUS
 CN Carbamic acid, [(1S)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913642-29-2 CAPLUS

CN Carbamic acid, [2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 913642-30-5 CAPLUS


CN Carbamic acid, [2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 913642-64-5 CAPLUS

CN Carbamic acid, [(1R)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-(2-furanylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913642-65-6 CAPLUS

CN Carbamic acid, [(1R)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-(2-furanylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913642-72-5 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]ethyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913642-73-6 CAPLUS


CN Carbamic acid, [(1S)-1-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-2-(3-pyridinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913642-75-8 CAPLUS

CN Imidodicarbonic acid, N-[2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-4-phenylbutyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:369222 CAPLUS

DOCUMENT NUMBER: 142:430279

TITLE: Preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors

INVENTOR(S): Lee, Dennis; Stavenger, Robert A.; Goodman, Krista B.; Hilfiker, Mark A.; Cui, Haifeng; Viet, Andrew Q.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037197	A2	20050428	WO 2004-US32824	20041006
WO 2005037197	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1675552	A2	20060705	EP 2004-794238	20041006
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007507546	T	20070329	JP 2006-534264	20041006
PRIORITY APPLN. INFO.:			US 2003-508894P	P 20031006
			US 2003-531949P	P 20031223
			WO 2004-US32824	W 20041006
OTHER SOURCE(S):			CASREACT 142:430279; MARPAT 142:430279	
GI				




AB Title compds. I [wherein X = (un)substituted NH, O, S, SO or SO₂; R₁, R₂ = (un)substituted alkyl, Ph, heteroaryl, etc.; and physiol. acceptable salts thereof] were prepared as Rho-kinase inhibitors. For example, 2,4-dichloro-5-nitropyridine (preparation given) underwent substitution with aniline (71% yield) and 3-acetylaminophenol (97% yield) subsequently followed by nitro reduction with H₂ in the presence of Pd/C to give II (100% yield). Conversion of this compound into III was realized via EDCI-mediated coupling with cyanoacetic acid, thermal intramol. cyclization to an 2-imidazoeacetonitrile (65% yield for the two steps), reaction with NaNO₂-HCl in methanol to an oxime (95% yield), and cyclization with NH₂OH in the presence of Et₃N (40% yield). The invented compds. are useful for the treatment of diseases, such as hypertension, heart failure and ischemic angina.

IT 850663-87-5P, 2-(4-Aminofurazan-3-yl)-1-ethyl-N-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-amine 850664-41-4P, 4-[1-Ethyl-6-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-48-1P, N-[2-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]ethyl]acetamide 850664-56-1P 850665-15-5P, 4-[1-Ethyl-6-[(phenylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)


RN 850663-87-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-6-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 850664-41-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850664-48-1 CAPLUS


CN Acetamide, N-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]ethyl]- (CA INDEX NAME)



RN 850664-56-1 CAPLUS


CN L-Proline, 1-[(2S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-2-methyl-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 850665-15-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(phenylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:120747 CAPLUS
DOCUMENT NUMBER: 142:219283
TITLE: Preparation of 1H-imidazo[4,5-c]pyridin-2-yl
derivatives as inhibitors of Akt activity
INVENTOR(S): Heerding, Dirk A.; Clark, Tammy J.; Drewry, David H.;
Leber, Jack Dale; Safonov, Igor; Yamashita, Dennis S.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011700	A1	20050210	WO 2004-US24340	20040728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261214	A1	20050210	AU 2004-261214	20040728
CA 2534038	A1	20050210	CA 2004-2534038	20040728
EP 1653961	A1	20060510	EP 2004-779406	20040728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004012993	A	20061003	BR 2004-12993	20040728
CN 1859912	A	20061108	CN 2004-80028355	20040728
JP 2007500709	T	20070118	JP 2006-522030	20040728
IN 2006DN00264	A	20070810	IN 2006-DN264	20060116
MX 2006PA01134	A	20060411	MX 2006-PA1134	20060127
NO 2006000985	A	20060419	NO 2006-985	20060228
PRIORITY APPLN. INFO.:			US 2003-490851P	P 20030729
			US 2003-491055P	P 20030730
			US 2003-493101P	P 20030806
			US 2003-494752P	P 20030813
			US 2003-507014P	P 20030929
			US 2003-530847P	P 20031218
			WO 2004-US24340	W 20040728
OTHER SOURCE(S):			CASREACT 142:219283; MARPAT 142:219283	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Het = 4-furazan-3-yl, 4-pyridinyl, 2-aminopyridin-4-yl, 2-amino-pyrimidin-5-yl, etc.; R1 = H, (un)substituted alkyl, cycloalkyl containing 1-4 heteroatoms; R4 = H, halo, (un)substituted alkyl, cycloalkyl, poly/cyclic aromatic ring; R7 = H, CONR9R10 and derivs., SO2NR9R10 and derivs., N(CH2)mNR9R10etc.; m = 6, where the carbon chain formed by m is optionally substituted; R9, R10 = independently H, (un)substituted alkyl, cycloalkyl etc.; with the exception of one compound;

and their pharmaceutically acceptable salts, hydrates, solvates, and prodrugs] were prepared as inhibitors of protein kinase B activity. For example, II•xTFA was prepared via cyclocondensation of N-(1-Benzylpiperidin-4-yl)-2-chloropyridin-3,4-diamine (preparation given) with Et cyanoacetate, followed by Pd-coupling with Ph boronic acid, reaction with NaNO₂ and NH₂OH of acetonitrile intermediate, and Bn-deprotection. In an Akt inhibitory activity assay, III displayed IC₅₀ values of 0.069, 0.038, and 0.032, against delta-PH domain of Akt1, Akt2, and Akt3, resp. Thus, I are useful in the treatment of cancer and arthritis (no data).



IT 842149-75-1P, Diethyl 1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-1,2-hydrazinedicarboxylate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Akt inhibitor; preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as inhibitors of Akt activity for treating cancer and arthritis)
 RN 842149-75-1 CAPLUS
 CN 1,2-Hydrazinedicarboxylic acid, 1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, 1,2-diethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:777793 CAPLUS
 DOCUMENT NUMBER: 139:292251
 TITLE: Preparation of imidazopyridines as kinase inhibitors
 INVENTOR(S): Bailey, Nicholas; Bamford, Mark James; Garland, Stephen; Goodman, Krista B.; Haifeng, Cui; Hilfiker, Mark A.; Lee, Dennis; Panchal, Terence Aaron; Stavenger, Robert A.; Wilson, David Matthew; Witherington, Jason
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 187 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080610	A1	20031002	WO 2003-GB1205	20030321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003215753	A1	20031008	AU 2003-215753	20030321
EP 1490367	A1	20041229	EP 2003-744904	20030321
EP 1490367	B1	20080723		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005526802	T	20050908	JP 2003-578364	20030321
US 20050197328	A1	20050908	US 2004-508760	20040922
US 7348339	B2	20080325		
PRIORITY APPLN. INFO.:			GB 2002-6860	A 20020322
			WO 2003-GB1205	W 20030321
OTHER SOURCE(S):	MARPAT 139:292251			
GI				



AB This patent concerns imidazopyridines (shown as I; variables defined below; e.g. 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-ylamine) and physiol. acceptable salts and or N-oxides thereof, processes for their preparation, pharmaceutical compns. containing them and their use in medicine.

For


I, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X2, X3 and X4 = N; R1 is a 5-, or 6-membered heterocyclic group II, III, IV or V wherein X5 is a N or CR7; and X6 is a O, S or NR8; X7 and X8, which may be the same or different is a N or CR9; X9 is a O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and = N or R11; addnl. details are given in the claims. For Rho-kinase (ROCK) activity the compds. I of the examples have a pIC50 of 9 to 5.2; for mitogen and stress activated protein kinase-1 (Msk-1) activity the compds. I of the examples have a pIC50 value of 9.28-5.15. The compds. I are essentially non-toxic at therapeutically useful doses; thus no adverse effects were observed when compds. of the invention were administered to rats at a dose of 100 mg/kg. Although no specific therapeutic applications are claimed, because of the inhibition by I of Msk-1, I should be useful for the treatment or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events or inflammatory conditions, e.g. cerebral stroke; also, because of the inhibition by I of Rho kinases, I should be useful for the treatment or prophylaxis of cardiovascular and neuroinflammatory diseases. More than 300 example preps. and/or characterization data for I are included. For example, [4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine was prepared in 4 steps (88, 94, 37 and 43 % yields, resp.) starting from 4-methoxy-3-nitropyridine hydrochloride and ethylamine and involving intermediates ethyl(3-nitropyridin-4-yl)amine, N'-ethylpyridine-3,4-diamine and (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile.

IT 607373-85-3P, [4-(1-Ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607373-97-7P, [4-[1-Ethyl-6-(methylsulfanyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyridines as kinase inhibitors)


RN 607373-85-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 607373-97-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(methylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:29:06 ON 11 AUG 2008)

FILE 'REGISTRY' ENTERED AT 09:29:15 ON 11 AUG 2008

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 178 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:29:49 ON 11 AUG 2008

L4 5 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

29.65

208.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.00

-4.00

STN INTERNATIONAL LOGOFF AT 09:32:48 ON 11 AUG 2008